- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07796503
TSBL-Based Versus BMI-Based Biliopancreatic Limb Length in One-Anastomosis Gastric Bypass (TSBL-OAGB)
TSBL-Based Versus BMI-Based Biliopancreatic Limb Length in One-Anastomosis Gastric Bypass: Interim Results of a Randomized Trial
Studieöversikt
Status
Betingelser
Detaljerad beskrivning
This is a single-center, prospective, randomized controlled trial comparing two methods for determining biliopancreatic limb length (BPLL) during laparoscopic one-anastomosis gastric bypass (OAGB) in patients with morbid obesity. Eligible patients aged 18-65 years with BMI ≥35 kg/m² (non-Asian) or ≥32.5 kg/m² (Asian populations) who were candidates for primary OAGB were randomized 1:1 using a computer-generated randomization sequence with sequentially numbered, opaque sealed envelopes.
In the intervention (TSBL-based) group, total small bowel length (TSBL) was measured intraoperatively from the ligament of Treitz to the ileocecal valve, and BPLL was calculated as 0.35 × TSBL. In the control (BMI-based) group, BPLL was determined using standard fixed lengths based on BMI category (150 cm, 180 cm, or 200 cm). All other surgical steps were identical between groups.
The primary outcome is percentage excess weight loss (%EWL) assessed longitudinally at baseline, 3, 6, and 12 months. Secondary outcomes include percentage total weight loss (%TWL), BMI, BMI loss, improvement of obesity-related comorbidities, and postoperative complications graded using the Clavien-Dindo classification. Statistical analysis uses linear mixed models to evaluate effects of group, time, and group-by-time interaction.
Because blinding of patients and surgeons was not feasible given the nature of the surgical intervention, outcome assessment relied on objective anthropometric and clinical measures. This record reflects a planned interim analysis conducted on the first 75 of a planned total of 100 enrolled patients, with 51 patients having completed 12-month follow-up at the time of this analysis.
Studietyp
Inskrivning (Beräknad)
Fas
- Inte tillämpbar
Kontakter och platser
Studiekontakt
- Namn: Nurbol Orynbassar
- Telefonnummer: +77474528797
- E-post: nurbolorynbassar@gmail.com
Studieorter
-
-
-
Almaty, Kazakstan
- Rekrytering
- JSC "National Scientific Center of Surgery named after A.N. Syzganov"
-
Kontakt:
- Nurbol Orynbassar
- Telefonnummer: +77474528797
- E-post: nurbolorynbassar@gmail.com
-
Huvudutredare:
- Adil Shokebaev
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Beskrivning
Inclusion Criteria:
- Age between 18 and 65 years
- BMI ≥35 kg/m² in non-Asian populations or ≥32.5 kg/m² in Asian populations
- Presence or absence of metabolic comorbidities (including type 2 diabetes, hypertension, and dyslipidaemia)
- Eligibility for primary one-anastomosis gastric bypass (OAGB)
- Provision of written informed consent
Exclusion Criteria:
- BMI below the defined thresholds
- Severe decompensated cardiac, pulmonary, hepatic, or renal disease
- Acute inflammatory conditions
- Active gastric or duodenal ulcer
- Psychiatric disorders or substance abuse
- Pregnancy or breastfeeding
- Active malignancy
- Severe intra-abdominal adhesions due to prior surgery
- Secondary obesity related to hypothalamic-pituitary-adrenal axis disorders
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: TSBL-Based Group
Biliopancreatic limb length (BPL) individualized based on intraoperatively measured total small bowel length (TSBL), calculated as BPL = 0.35 × TSBL.
|
Biliopancreatic limb length individualized intraoperatively based on measured total small bowel length (TSBL), calculated as BPL = 0.35 × TSBL, prior to laparoscopic one-anastomosis gastric bypass.
|
|
Aktiv komparator: BMI-Based Group
Biliopancreatic limb length (BPL) determined using standard fixed lengths based on BMI category: 150 cm for BMI 35-39.9,
180 cm for BMI 40-49.9,
200 cm for BMI ≥50.
|
Biliopancreatic limb length determined using standard fixed lengths based on preoperative BMI category (150 cm, 180 cm, or 200 cm), prior to laparoscopic one-anastomosis gastric bypass.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Percentage of Excess Weight Loss (%EWL)
Tidsram: Baseline, 3 months, 6 months, and 12 months post-surgery
|
EWL defined as the proportion of weight loss relative to excess baseline weight, with ideal body weight defined as BMI 25 kg/m².
Assessed longitudinally over time using linear mixed models.
|
Baseline, 3 months, 6 months, and 12 months post-surgery
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Percentage of Total Weight Loss (%TWL)
Tidsram: Baseline, 3 months, 6 months, and 12 months post-surgery
|
TWL assessed as percentage of total body weight loss relative to baseline weight.
Assessed longitudinally over time using linear mixed models.
|
Baseline, 3 months, 6 months, and 12 months post-surgery
|
|
BMI Change
Tidsram: Baseline, 3 months, 6 months, and 12 months post-surgery
|
Change in body mass index (BMI, kg/m²) from baseline over time.
|
Baseline, 3 months, 6 months, and 12 months post-surgery
|
|
BMI Loss (BMIL)
Tidsram: Baseline, 3 months, 6 months, and 12 months post-surgery
|
Reduction in BMI from baseline, expressed as BMI loss (BMIL).
|
Baseline, 3 months, 6 months, and 12 months post-surgery
|
|
Improvement in Obesity-Related Comorbidities
Tidsram: 12 months post-surgery
|
Change in obesity-related comorbidities, including hypertension and ischemic heart disease, compared between groups.
|
12 months post-surgery
|
|
Postoperative Complications
Tidsram: 12 months post-surgery
|
Postoperative complications documented and categorized according to the Clavien-Dindo classification system, including anaemia, hair loss, and bowel movement disorder.
|
12 months post-surgery
|
Samarbetspartners och utredare
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- TSBL-BMI-OAGB
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
IPD-planbeskrivning
Tidsram för IPD-delning
Kriterier för IPD Sharing Access
IPD-delning som stöder informationstyp
- STUDY_PROTOCOL
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .